IMMUNOMEDICS INC - FORM 10-Q - EX-32.1 - EXHIBIT 32.1 CERTIFICATIONS OF CEO AND CFO: SECTION 906 - November 7, 2018

Attached files

file filename
EX-10.62 - EXHIBIT 10.62 NONQUALIFIED STOCK OPTION GRANT, DATED AS OF SEPTEMBER 24, 2018 - IMMUNOMEDICS INCimmu-09302018ex1062.htm
EX-31.2 - EXHIBIT 31.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER: SECTION 302 - IMMUNOMEDICS INCimmu-09302018ex312.htm
EX-31.1 - EXHIBIT 31.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER: SECTION 302 - IMMUNOMEDICS INCimmu-09302018ex311.htm
EX-10.65 - EXHIBIT 10.65 IMMUNOMEDICS, INC. ANNUAL CASH BONUS PLAN - IMMUNOMEDICS INCimmu-09302018ex1065.htm
EX-10.64 - EXHIBIT 10.64 NONQUALIFIED STOCK OPTION GRANT, DATED AS OF JULY 11, 2018 - IMMUNOMEDICS INCimmu-09302018ex1064.htm
EX-10.63 - EXHIBIT 10.63 EXECUTIVE EMPLOYMENT AGREEMENT, DATED AS OF SEPTEMBER 26, 2018 - IMMUNOMEDICS INCimmu-09302018ex1063.htm
EX-10.61 - EXHIBIT 10.61 EXECUTIVE EMPLOYMENT AGREEMENT, DATED AS OF SEPTEMBER 24, 2018 - IMMUNOMEDICS INCimmu-09302018ex1061.htm
EX-10.60 - EXHIBIT 10.60 PRODUCT SPECIFIC AGREEMENT, DATED AS OF SEPTEMBER 11, 2018 - IMMUNOMEDICS INCimmu-9302018ex1060.htm
EX-10.59 - EXHIBIT 10.59 MASTER SERVICES AGREEMENT, DATED AS OF SEPTEMBER 11, 2018 - IMMUNOMEDICS INCimmu-09302018ex1059.htm
EX-10.58 - EXHIBIT 10.58 TRANSITION AGREEMENT, DATED AS OF AUGUST 23, 2018 - IMMUNOMEDICS INCimmu-09302018ex1058.htm
EX-10.57 - EXHIBIT 10.57 FORM OF EXCHANGE AGREEMENT, DATED OCTOBER 2, 2018 - IMMUNOMEDICS INCimmu-09302018ex1057.htm
10-Q - 10-Q - IMMUNOMEDICS INCimmu-0930201810q.htm


Exhibit 32.1
 
Certification
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
 
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of Immunomedics, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:
 
The Form 10-Q for the quarter ended September 30, 2018, (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
 
 
Dated:  November 7, 2018
/s/ Michael Pehl
 
Michael Pehl
 
Chief Executive Officer
 
 
 
 
Dated:  November 7, 2018
/s/ Usama Malik
 
Usama Malik
 
Principal Financial Officer
 
 
 
 
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.



Stock widget

Investing forum

IMMUNOMEDICS INC Reports